Pompano Beach, FL -- (SBWIRE) -- 12/11/2012 -- Rentech, Inc. (NYSE:RTK) is currently trading at $2.96, 1.19% higher. Rentech, Inc. (Rentech) is a provider of clean energy solutions. The Company owns and operates a nitrogen fertilizer plant in East Dubuque, Illinois, that manufactures and sells natural gas-based nitrogen fertilizer products within the corn-belt region in the United States. It is developing energy projects to produce certified synthetic fuels and electric power from carbon-containing materials, such as biomass, waste and fossil resources.
Will RTK Continue to Jump? Get Our Special Report To Get complete technical analysis on RTK go click my link
Hemispherx BioPharma, Inc (NYSE:HEB) added 7.74% to $0.668. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.
Get Free Trend Analysis on HEB go click my link
Cheniere Energy, Inc. (NYSE:LNG) is higher 0.62% to $17.88. Cheniere Energy, Inc. (Cheniere) is an energy company primarily engaged in liquid natural gas (LNG)-related businesses. The Company operates in three segments: LNG terminal business, natural gas pipeline business, and LNG and natural gas marketing business. The Company owns and operates the Sabine Pass LNG terminal in Louisiana through its 88.8% ownership interest in Cheniere Energy Partners, L.P. (Cheniere Partners).
To Get complete technical analysis on LNG go click my link
Avalon Rare Metals Inc (US listing) (NYSE:AVL) among the gainers and the stock added 5.75% to $1.47. Avalon Rare Metals Inc. (Avalon) is a Canada-based mineral exploration and development company. The Company’s primary focus is on rare metals and minerals, including tin, lithium, tantalum, niobium, cesium, indium, gallium, zirconium and calcium feldspar. It is in the process of exploring or developing three of its six mineral resource properties.
Get Free Trend Analysis on AVL go click my link
YM BioSciences Inc. (USA) (NYSE:YMI) is lower 1.22% to $1.62. YM BioSciences Inc. (YM), is a drug development company. The Company is advancing three clinical-stage hematology and cancer-related products. Its CYT387, is an oral small molecule oral dual inhibitor of the JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody, and CYT997, a vascular disrupting agent (VDA). The Company conducts and outsources clinical trials and also out source the manufacture of clinical materials to third parties.
To Get complete technical analysis on YMI go click my link
Csrnewsdaily.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.
Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.
The assembled information disseminated by Csrnewsdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Csrnewsdaily.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)